Patient clinical data including underlying epilepsy syndrome, seizure type, and antiepileptic medications
| Patient | Age (yr) | Epilepsy Syndrome21–23 | Seizure Type | Medications |
|---|---|---|---|---|
| 1 | 1 | EE (Unclassified) | T | LEV |
| 2 | 2 | Metabolic (Mito) | TS | ZNS/LTG/LEV |
| 2 | 7 | Metabolic (Mito) | TS/GTC | ZNS/LTG/LEV/RFM |
| 2 | 8 | Metabolic (Mito) | TS/MY/GTC | ZNS/LTG/LEV/RFM |
| 3 | 9 | MAE | MY/AT/GTC | VPA/CLB/RFM |
| 4 | 7 | Metabolic (Mito) | MY/RFL | TPM |
| 4 | 10 | Metabolic (Mito) | MY/RFL | TPM/ZNS |
| 5 | 7 | EE (MCD) | T/AT/TS | VGB/LTG |
| 6 | 2 | Structural (MCD) | Focal | ZNS/TPM |
| 7 | 1 | Structural (Aicardi) | ES | VGB |
| 8 | 6 | Genetic (SCN1A) | MY/AT | LEV/ETX/CLN |
| 9 | 6 | Metabolic (Mito) | MY/AT | LEV/LTG/ETX/CLN |
| 10 | 6 | MAE | T/MY/TS | LTG |
| 11 | 0.5 | Genetic (ATP1A3) | Focal/SE | LEV |
| 11 | 1 | Genetic (ATP1A3) | SUB/MY | LTG/CLB |
| 12 | 6 | EE (unclassified) | AT/T/GTC | CLB |
| 13 | 1 | EE (unclassified) | ES | VGB |
| 14 | 2 | Metabolic (Mito) | ES | TPM |
| 15 | 4 | EE (LGS) | AT/T/AA | LTG/LEV/ZNS |
| 16 | 1 | EE (Unclassified) | ES | ZNS/LEV |
| 17 | 5 | Genetic (DEAF 1) | T/AT/GTC | LEV |
| 18 | 1 | Metabolic (Mito) | ES | ZNS |
Note:—“Epilepsy Syndrome”: EE indicates epileptic encephalopathy; Mito, primary mitochondrial disease; MAE, myoclonic astatic epilepsy; MCD, malformation of cortical development; LGS, Lennox-Gastaut Syndrome; “Seizure Type”: T, tonic; TS, tonic spasms; GTC, generalized tonic-clonic; MY, myoclonic; AT, atonic; RFL, reflexive seizure; ES, epileptic spasms; SE, status epilepticus; AA, atypical absence; SUB, subclinical seizures; “Medications”: LEV, levetiracetam; ZNS, zonisamide; LTG, lamotrigine; RFM, rufinamide; CLB, clobazam; TPM, topiramate; VGB, vigabatrin; ETX, ethosuximide; CLN, clonazepam; VPA, valproic acid.